يرجى استخدام متصفح الكمبيوتر الشخصي للوصول إلى التسجيل - تداول السعودية
حسنًا
Reported Sunday, Rhythm Pharmaceuticals To Reveal Topline Results From Pivotal Phase 3 TRANSCEND Trial Of Setmelanotide In Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals -3.45%
Rhythm Pharmaceuticals RYTM | 113.56 | -3.45% |
Reported Sunday, Rhythm Pharmaceuticals To Reveal Topline Results From Pivotal Phase 3 TRANSCEND Trial Of Setmelanotide In Acquired Hypothalamic Obesity
